Indaptus Therapeutics, Inc. (NASDAQ:INDP) Stock Short Interest Jumps 331.5%
by Danessa Lincoln · The Markets DailyIndaptus Therapeutics, Inc. (NASDAQ:INDP – Get Free Report) saw a significant growth in short interest during the month of September. As of September 15th, there was short interest totaling 916,352 shares, a growth of 331.5% from the August 31st total of 212,357 shares. Based on an average daily volume of 2,311,369 shares, the short-interest ratio is currently 0.4 days. Currently, 0.8% of the shares of the stock are short sold.
Indaptus Therapeutics Stock Performance
Indaptus Therapeutics stock traded down $0.15 during midday trading on Friday, hitting $3.85. 570,038 shares of the company’s stock were exchanged, compared to its average volume of 1,495,965. The firm has a 50-day moving average of $1.94 and a two-hundred day moving average of $2.25. Indaptus Therapeutics has a 12 month low of $0.92 and a 12 month high of $8.57. The company has a market cap of $512.97 million, a PE ratio of -0.61 and a beta of 1.17.
Indaptus Therapeutics (NASDAQ:INDP – Get Free Report) last announced its earnings results on Thursday, August 13th. The company reported ($0.02) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.57) by $1.55.
Wall Street Analyst Weigh In
Several equities analysts have commented on the stock. Wall Street Zen upgraded shares of Indaptus Therapeutics to a “hold” rating in a research report on Saturday, June 27th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Indaptus Therapeutics in a report on Friday, July 17th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock currently has an average rating of “Sell”.
Get Our Latest Research Report on Indaptus Therapeutics
About Indaptus Therapeutics
Indaptus Therapeutics, Inc is a clinical-stage biotechnology company focused on developing novel immunotherapies for cancer and other serious diseases. The company’s approach is designed to activate the body’s innate and adaptive immune systems to generate a broad, potentially durable therapeutic response.
Indaptus’s lead platform, Decoy20, is based on an engineered formulation of inactivated bacteria intended to stimulate immune cells without causing an active infection. The company has been evaluating Decoy20 as a treatment for advanced solid tumors, including in combination with other cancer therapies.